Details for Patent: 8,354,427
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,354,427 protect, and when does it expire?
Patent 8,354,427 protects KALYDECO, SYMDEKO (COPACKAGED), and TRIKAFTA (COPACKAGED), and is included in four NDAs.
This patent has one hundred and twenty-one patent family members in twenty-six countries.
Summary for Patent: 8,354,427
Title: | Modulators of ATP-binding cassette transporters |
Abstract: | The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. |
Inventor(s): | Van Goor; Fredrick (San Diego, CA) |
Assignee: | Vertex Pharmaceutical Incorporated (Cambridge, MA) |
Application Number: | 12/635,927 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,354,427
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING CYSTIC FIBROSIS | See Plans and Pricing | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE | See Plans and Pricing | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,354,427
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2005258320 | See Plans and Pricing | |||
Australia | 2010249302 | See Plans and Pricing | |||
Australia | 2010251787 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |